

HEDIS^{®1}: Disease-modifying Anti-rheumatic Drug Therapy for Rheumatoid Arthritis (ART)

Description of the measure

Patients at least 18 years old who were diagnosed with rheumatoid arthritis (RA) and were dispensed at least one ambulatory prescription for a disease-modifying anti-rheumatic drug (DMARD) during the measurement year.

Exclusion(s)

- Hospice
- A diagnosis of HIV any time during the member’s history
- A diagnosis of pregnancy any time during the measurement year

Tips for best practices

- **Confirm the diagnosis of RA:**
 - Refer patient to a rheumatologist who will order a CCP (Cyclic Citrullinated Peptide Antibody) and Rheumatoid Factor Blood tests to confirm the diagnosis
- **If incorrectly diagnosed with RA:**
 - A corrected claim needs to be issued and an addendum to chart notes should be made
- **If correctly diagnosed with RA:**
 - Prescribe an appropriate DMARD from list below:

Drug category	Medication name		
5-Aminosalicylates	Sulfasalazine		
Alkylating agents	Cyclophosphamide		
Aminoquinolines	Hydroxychloroquine		
Anti-rheumatics	Auranofin Leflunomide	Penicillamine Methotrexate	
Immunomodulators	Abatacept Certolizumab pegol Infliximab	Rituximab Adalimumab Etanercept Sarilumab	Tocilizumab Anakinra Golimumab
Immunosuppressive agents	Azathioprine Mycophenolic acid	Cyclosporine	Mycophenolate mofetil
Janus kinase (JAK) inhibitor	Tofacitinib	Baricitnib	Upadacitinib
Tetracyclines	Minocycline		

¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA).